Saturday 17 October 2026
Export GYRE’s income statement to Excel — free account
Gyre Therapeutics, Inc.
GYRE Healthcare Biotechnology
In the quarter to June 2026, revenue fell 2.12%, EPS was flat and free cash flow fell 130.5%, each against the same quarter a year earlier.
6.08
0.32
−5.00%
Follow GYRE
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
106.57 | 141.20 | 0.00 | 0.00 |
P/S ratio |
6.15 | 5.41 | 5.44 | 5.70 | |
P/FCF ratio |
450.03 | 0.00 | 207.39 | 0.00 | |
P/Operating CF |
47.60 | (112.14) | 200.15 | (39.65) | |
P/B ratio |
4.93 | 10.59 | 4.65 | 4.65 | |
Price to Tangible BV |
5.11 | 11.51 | 4.81 | 4.81 | |
EV/Sales |
5.65 | 4.66 | 5.06 | 5.10 | |
EV/EBITDA |
62.60 | 38.79 | 235.25 | 0.00 | |
EV/Operating CF |
160.67 | 537.99 | 137.05 | (120.29) | |
EV/FCF |
413.62 | (615.37) | 192.86 | (83.33) | |
Quick Ratio |
5.41 | 5.21 | 3.68 | 3.59 | |
Current Ratio |
6.19 | 6.28 | 4.64 | 4.26 | |
Net Debt/EBITDA |
(8.28) | (17.74) | 5.74 | 5.80 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.77 | 0.68 | 0.80 | 0.66 | |
Operating CF/Net income |
3.94 | (7.37) | (0.37) | 1.43 | |
Capex/Depreciation |
(1.86) | (0.19) | (0.26) | (0.87) | |
Interest Coverage |
— | — | — | (15.23) | |
Research and Development Expense of Revenue |
7.73% | (0.32%) | 29.92% | 65.75% | |
Selling, General and Administrative Expense of Revenue |
64.28% | 81.99% | 94.84% | 74.29% | |
Intangible Assets out of Total Assets |
0.03 | 0.02 | 0.03 | 0.02 | |
Share Based Compensation of Revenue |
2.02% | 13.43% | 11.47% | 7.13% | |
Graham Net Nets |
0.11 | 0.19 | 0.10 | 0.13 | |
Graham Number |
1.54 | 0.87 | 0.00 | 0.00 | |
Earnings Yield |
0.94% | 0.71% | (1.15%) | (3.03%) | |
Free Cash Flow Yield |
0.22% | (0.14%) | 0.48% | (1.07%) | |
Revenue per Share |
0.34 | 0.38 | 0.25 | 0.29 | |
Operating CF per Share |
0.16 | (0.06) | 0.03 | (0.17) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | (0.01) | |
Free Cash Flow per Share |
0.15 | (0.06) | 0.03 | (0.18) | |
Cash per Share |
0.66 | 1.04 | 0.55 | 0.74 | |
Shareholders Equity per Share |
1.51 | 2.11 | 1.50 | 1.64 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.51 | 2.11 | 1.50 | 1.64 | |
Free Cash Flow |
13.63 | (5.75) | 3.00 | (18.01) | |
Working Capital |
82.66 | 125.58 | 71.94 | 93.41 | |
Capital Expenditures |
(0.60) | (0.13) | (0.18) | (1.28) | |
Net Current Asset Value |
76.61 | 117.96 | 66.70 | 87.74 | |
EV/EBIT |
81.69 | 47.30 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.00 | 0.01 | 0.04 | |
Price to Operating Income |
88.88 | 54.91 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
23.44 | 28.04 | 21.69 | 26.44 | |
Average Payables |
0.43 | 0.72 | 0.19 | 0.65 | |
Average Inventory |
7.62 | 8.25 | 9.62 | 10.14 | |
Average Assets |
142.31 | 172.58 | 145.90 | 175.95 | |
Average Common Equity |
117.94 | 78.97 | 120.64 | 135.97 |
Columns are period end dates